PMID: 8604444Mar 1, 1996Paper

Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: an antagonist's viewpoint

Progress in Cardiovascular Diseases
J L Anderson

Abstract

Despite their intuitive appeal, implantable cardioverter defibrillator s (ICDs) will require testing in randomized studies to establish their relative value as compared with antiarrhythmic drugs in patients with life-threatening ventricular tachyarrhythmias (ventricular tachycardia/ventricular fibrillation [VT/VF]). In these studies, only total mortality is an acceptable primary end point. Lessons from recent drug studies (CAST, ESVEM, CASCADE) have shown that class-III/beta-receptor antagonist therapy is superior to class-I drugs selected by electrophysiologic or Holter monitor testing. Thus, sotalol or amiodarone should now be considered first-line drugs for VT/VF therapy. Advantages of contemporary drug therapy for VT/VF include wide experience among clinicians, progressively better drugs, lower cost, universal availability, greater flexibility in use (easy to start, titrate, and stop), ability to suppress (not just terminate) events, and favorable effect on disease progression (eg, beta-blockade effects in cardiomyopathy and ischemic heart disease). Recent matched observational studies and a small randomized experience (CASH) suggest near equivalence in total mortality in ICD and drug-treated groups. Until or unless modifie...Continue Reading

References

May 1, 1992·The American Journal of Medicine·E J Eichhorn
Apr 1, 1992·The American Journal of Cardiology·D NewmanJ C Griffin
May 1, 1989·Journal of the American College of Cardiology·R A WinkleT Shipman
Mar 1, 1995·The American Journal of Cardiology·A P HallstromUNKNOWN AVID Investigators
Nov 26, 1993·The American Journal of Cardiology·A J CammG Frangin

❮ Previous
Next ❯

Citations

Mar 1, 1996·Progress in Cardiovascular Diseases·J W MasonD Mann
May 14, 2003·Journal of the American College of Cardiology·Douglas S LeeDavid A Alter
Dec 11, 1997·Pacing and Clinical Electrophysiology : PACE·R A MarinchakP R Kowey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.